550 results match your criteria: "AOU University of Campania "Luigi Vanvitelli"[Affiliation]"

Background And Aims: Few reports, all retrospective, have evaluated vaccine coverage against COVID-19 infection in cirrhotic subjects. No data are available for European Countries. We aimed to explore this topic and potential independent predictors of lack of vaccination.

View Article and Find Full Text PDF

Data-driven clustering of combined Functional Motor Disorders based on the Italian registry.

Front Neurol

November 2022

Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Introduction: Functional Motor Disorders (FMDs) represent nosological entities with no clear phenotypic characterization, especially in patients with multiple (combined FMDs) motor manifestations. A data-driven approach using cluster analysis of clinical data has been proposed as an analytic method to obtain non-hierarchical unbiased classifications. The study aimed to identify clinical subtypes of combined FMDs using a data-driven approach to overcome possible limits related to "a priori" classifications and clinical overlapping.

View Article and Find Full Text PDF

Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey.

Neurology

March 2023

From the Pediatric Neurology (Giorgia Coratti, M.R., A.C., M.C.P., M.D.P., E.M.), Università Cattolica del Sacro Cuore, Rome; Centro Clinico Nemo (Giorgia Coratti, M.R., A.C., M.C.P., M.D.P., E.M.), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Department of Neurosciences (A.D.), Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome; The NEMO Center in Milan (V.S.), Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Italy; Center of Translational and Experimental Myology (C.B.), and Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genova, IRCCS Istituto Giannina Gaslini; Department of Clinical and Experimental Medicine (S.M.), University of Messina; AOU Città della Salute e della Scienza di Torino (F.R., T.M.), presidio Molinette e OIRM (SS Malattie Neuromuscolari e SC Neuropsichiatria Infantile), Turin; Department of Neurological Sciences (M.C.), AOU Ospedali Riuniti di Ancona; AOU Pisana (Department of Clinical and Experimental Medicine) (G.S.), Neurology Unit, Pisa; Neurology Unit (E.P.), Azienda Ospedale Padova, Padua; Department of Neurology/Stroke Unit (M.T.), Bolzano Hospital, Trentino-Alto Adige; Department of Clinical and Experimental Sciences (M.F.), University of Brescia; NeMO-Brescia Clinical Center for Neuromuscular Diseases (M.F.), Brescia; Neurology Unit (Giacomo Comi), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; Dino Ferrari Center (Giacomo Comi), Department of Pathophysiology and Transplantation, University of Milan; Fondazione IRCCS Istituto Neurologico Carlo Besta Developmental Neurology Unit (R.M.), Milan; Neuroimmunology and Neuromuscular Disorders Unit (L.M.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; Institute for Maternal and Child Health (I.B.), IRCCS, Burlo Garofolo, Trieste; NeuroMuscular Unit (M.G.D.A.), Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco; Scientific Institute IRCCS "E. Medea" (A.T.), Unit for Severe disabilities in developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Brindisi; UOC Clinica Neurologica (V.V.), IRCCS Institute of Neurological Sciences of Bologna, Emilia-Romagna; Metabolic Unit (M.D.), A. Meyer Children's Hospital, Florence; Neurology Unit (I.S.), Azienda Ospedaliero-Universitaria, Policlinico Bari "Amaducci", Bari; Department of Neurosciences (L.R.), Reproductive Sciences and Odontostomatology, University of Naples Federico II; Department of Neurosciences (A.V.), Pediatric Neurology, Santobono-Pausilipon Children's Hospital, Naples; Neurology Unit (L.V.), Department of Neurosciences, University Hospital Santa Maria della Misericordia, Udine, Friuli-Venezia Giulia; Department of Child Neuropsychiatry (A.B.), Fondazione Istituto Neurologico Nazionale C Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Pavia; Dipartimento di Salute della Donna e del Bambino (C.A.), Università di Padova, Padua; IRCCS Istituto delleScienze Neurologiche di Bologna-UOC Neuropsichiatria Infantile (A.P.); Centro Sclerosi Multipla (M.A.M.), P.O. Binaghi, ASSL Cagliari; Cardiomyology and Medical Genetics Unit (L.P.), Università degli Studi della Campania Luigi Vanvitelli Scuola di Medicina e Chirurgia, Napoli; Section of Neurology (F.B.), Department of Biomedicine, Neuroscience, and Advanced Diagnostics (BiND), University of Palermo; Neurology Department (N.C.), Hospital San Francesco of Nuoro; Department of Neuroscience (M.G.), Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Sant'Andrea Hospital; Neuromuscular Omnicentre (NeMO) Trento-Fondazione Serena Onlus (R.Z.), Pergine Valsugana; Pediatric Neurology Unit (D.G.), Pediatric Hospital "Giovanni XXIII", Bari; Child Neuropsychiatry Unit (S.S.), Paediatric Hospital G Salesi, Ancona; Institute of Experimental Neurology (INSPE), Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan; National Centre for Rare Diseases (D.T.), Istituto Superiore di Sanità, Rome; and Sezione di Igiene (S.B.), Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy.

Article Synopsis
  • - The study focuses on spinal muscular atrophy (SMA), a genetic neurodegenerative disorder, aiming to determine its prevalence and treatment rates in Italy.
  • - An online survey was conducted across 36 Italian referral centers, revealing 1,255 SMA patients with an estimated prevalence of 2.12 per 100,000 people, categorized by SMA type and severity.
  • - Around 85% of patients received treatment, but the percentage varied by severity, showing higher treatment rates in more severe cases (95.77% for type I compared to 79.01% for type III).
View Article and Find Full Text PDF

"Transplantomics" for predicting allograft rejection: real-life applications and new strategies from Network Medicine.

Hum Immunol

February 2023

Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", 80138, Naples, Italy; U.O.C. Division of Clinical Immunology, Immunohematology, Transfusion Medicine and Transplant Immunology, Department of Internal Medicine and Specialistics, University of Campania "Luigi Vanvitelli", Naples, Italy.

Although decades of the reductionist approach achieved great milestones in optimizing the immunosuppression therapy, traditional clinical parameters still fail in predicting both acute and chronic (mainly) rejection events leading to higher rates across all solid organ transplants. To clarify the underlying immune-related cellular and molecular mechanisms, current biomedical research is increasingly focusing on "transplantomics" which relies on a huge quantity of big data deriving from genomics, transcriptomics, epigenomics, proteomics, and metabolomics platforms. The AlloMap (gene expression) and the AlloSure (donor-derived cell-free DNA) tests represent two successful examples of how omics and liquid biopsy can really improve the precision medicine of heart and kidney transplantation.

View Article and Find Full Text PDF

The emerging role of immunotherapy in the treatment of anal cancer.

Curr Opin Pharmacol

December 2022

Department of Gastrointestinal Oncology, Institut Jules Bordet, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium. Electronic address:

For decades, chemoradiotherapy for early-stage disease and systemic chemotherapy for advanced disease have represented the mainstay of treatment for anal cancer. Over the last few years, however, the advent of immunotherapy has opened interesting therapeutic perspectives, with the establishment of new standards of care, and the development of clinical trials that may further shape the treatment algorithm for this tumour. In this review article, we discuss the rationale behind the use of immunotherapy for anal cancer and provide an overview of the available clinical data and ongoing efforts to build on these.

View Article and Find Full Text PDF

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study.

J Neurol

February 2023

Unit of Headache and Neurosonology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128, Rome, Italy.

Introduction: Although migraine prevalence decreases with aging, some older patients still suffer from chronic migraine (CM). This study aimed to investigate the outcome of OnabotulinumtoxinA (OBT-A) as preventative therapy in elderly CM patients.

Methods: This is a post hoc analysis of real-life prospectively collected data at 16 European headache centers on CM patients treated with OBT-A over the first three treatment cycles (i.

View Article and Find Full Text PDF

Background. Evidence has shown a close association between COVID-19 infection and renal complications in both individuals with previously normal renal function and those with chronic kidney disease (CKD). Methods.

View Article and Find Full Text PDF

Hereditary prostate cancer (HPCa) has the highest heritability of any cancer in men. Interestingly, it occurs in several hereditary syndromes, including breast and ovarian cancer (HBOC) and Lynch syndrome (LS). Several gene mutations related to these syndromes have been identified as biomarkers in HPCa.

View Article and Find Full Text PDF
Article Synopsis
  • There is a lack of clinical trial data on the use of biologics for treating psoriasis in patients with a history of cancer, prompting this study on secukinumab treatment in such patients.
  • This observational study involved 42 adults with moderate-to-severe psoriasis, showing no tumor recurrence or progression, though three developed unrelated new malignancies during treatment.
  • Results indicated that a significant portion of participants achieved substantial improvements in psoriasis severity and quality of life after 48 weeks, supporting the safety and effectiveness of secukinumab for this patient group.
View Article and Find Full Text PDF

The Autoinflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases.

Front Med (Lausanne)

September 2022

Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.

Objective: The present manuscript aims to describe an international, electronic-based, user-friendly and interoperable patient registry for monogenic autoinflammatory diseases (mAIDs), developed in the contest of the Autoinflammatory Diseases Alliance (AIDA) Network.

Methods: This is an electronic platform, based on the Research Electronic Data Capture (REDCap) tool, used for real-world data collection of demographics, clinical, laboratory, instrumental and socioeconomic data of mAIDs patients. The instrument has flexibility, may change over time based on new scientific acquisitions, and communicate potentially with other similar registries; security, data quality and data governance are corner stones of the platform.

View Article and Find Full Text PDF
Article Synopsis
  • In people living with HIV, aging and long-term antiretroviral therapy (ART) have led to a rise in non-communicable chronic diseases due to chronic inflammation and immune activation.
  • A study analyzed data from 1,394 participants, focusing on the relationship between their age, age at starting ART, and duration of treatment with various health issues.
  • Results indicated that prolonged ART exposure increases risks of conditions like dyslipidemia, hypertension, and osteoporosis, highlighting the impact of these factors on overall health in older patients.
View Article and Find Full Text PDF

Background And Purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials.

View Article and Find Full Text PDF

Background: Patients with autoimmune systemic diseases (ASDs) represent a frail population during the ongoing COVID-19 pandemic. The vaccination is the major preventive measure; however, a significant number of ASD patients show an impaired production of anti-COVID-19 neutralizing antibodies (NAb), possibly counterbalanced by adequate T-cell response. The present study aimed at evaluating both humoral and cellular response to COVID-19 vaccine booster dose in this particular setting.

View Article and Find Full Text PDF

Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study.

J Clin Med

September 2022

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, 80131 Naples, Italy.

This study investigates longitudinal changes in health-related quality of life (HRQoL) in early-onset multiple sclerosis (MS) patients and explores the impact of disease activity (relapses) on such changes. People with MS (PwMS) onset between 12 and 25 years of age were followed longitudinally. At baseline and at year 4, patients were asked to fill the Paediatric Quality of life inventory (PedsQL).

View Article and Find Full Text PDF

Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors.

Int J Environ Res Public Health

September 2022

Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio 1 Coppito, 67100 L'Aquila, Italy.

Article Synopsis
  • The study focused on identifying chronic migraine patients who might benefit the most from onabotulinumtoxinA treatments, analyzing response rates in a multicenter European setting.
  • Excellent responders were categorized as those with either a significant drop in headache days (≥75%) or those experiencing infrequent headaches (<4 days/month), with about 10% and 5% of patients classified in each category, respectively.
  • Key findings indicated that excellent responders tended to have higher medication overuse and that female patients were less likely to be categorized as frequency-based excellent responders, suggesting that those without medication overuse or female patients might see less benefit from the treatment.
View Article and Find Full Text PDF

The COVID-19 pandemic caused by SARS-CoV-2 remains a significant issue for global health, the economy, and society. When SARS-CoV-2 began to spread, the most recent serious infectious disease of this century around the world, with its high morbidity and mortality rates, it is understandable why such infections have generally been spread in the past, mainly from international travel movements. This perspective review aimed to provide an update for clinicians on the recent developments related to the microbiological perspectives in pandemics, diagnostics, prevention (such as the spread of a virus), vaccination campaigns, treatment options, and health consequences for COVID-19 based on the current literature.

View Article and Find Full Text PDF

Post-Cerebrovascular Stroke and Early Dysphagia Assessment: A Systematic Review.

Acta Biomed

August 2022

Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", ENT Section, University of Catania, Catania, Italy..

Purpose: We performed a systematic review on the early assessment of swallowing function after cerebrovascular stroke.

Materials And Methods: A systematic review of the English language literature of the past 20 years was performed regarding swallowing function and cerebrovascular stroke. All articles reporting swallowing evaluation through clinical examination validated scores, and diagnostic tools were included in the summary.

View Article and Find Full Text PDF

In the present study, immunogenicity data in 61 vaccinated healthcare workers (HCWs) either infection naïve (naïve HCWs) or with infection of Delta and/or Omicron COVID-19 (experienced HCWs) were evaluated up to 270 days after the second dose of BNT162b2 vaccine and up to 90 days after a booster dose. A decrease in antibody levels at 270 days following administration of the second dose (p = 0.0335) was observed, although values did not fall below the positivity threshold (33.

View Article and Find Full Text PDF

The abscopal effect is defined as the systemic regression of distant neoplastic lesions induced by localized treatment. Although the first case reports date back to the beginning of the twentieth century, it remains a very rare event. In recent years, research and reporting on the subject has increased thanks to the development of new immune-checkpoint inhibitors (ICIs) and stereotactic body radiotherapy, as a consequence of molecular and clinical synergism.

View Article and Find Full Text PDF

Aim: The aim of the current study is to investigate the impact of primary compared to secondary chemotherapy-induced nausea and vomiting (CINV) prophylaxis with NK1 receptor antagonists (NK1-RA) in patients affected by gastrointestinal malignancies and treated with oxaliplatin- and/or irinotecan-based doublet or triplet regimens.

Study Design And Methods: Clinical data of patients affected by gastrointestinal malignancies, treated with an oxaliplatin and/or irinotecan-based doublet or triplet regimen as neo/adjuvant or advanced-line treatment, and who received NK1-RA as primary (from the first cycle of treatment) or secondary (after the onset of CINV with a previous regimen with 5HT3-RA and dexamethasone) prophylaxis for CINV, were retrospectively collected in an observational study involving 16 Italian centers. A propensity score matching was performed by taking into account the following stratification factors: sex (male vs.

View Article and Find Full Text PDF

Background: The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6-11 years with moderate-to-severe AD not adequately controlled with topical therapies or when those therapies are not advisable.

Objectives: The aim of this study was to evaluate in real life the effectiveness and safety of dupilumab in the treatment of children aged from 6 to 11 years.

View Article and Find Full Text PDF

Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review.

J Pers Med

August 2022

Otorhinolaryngology, Head and Neck Surgery Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy.

Background: So far, no medical treatment is available for cholesteatoma (C) and the only effective therapy is complete surgical removal, but recurrence is common even after surgical treatment. While C is classically divided into two clinical phenotypes, congenital and acquired, only a few studies have focused on its potential biomarkers. This study aims to revise the literature to identify which biomarkers can define the endotype of C.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to evaluate changes in body distribution and symptoms of functional motor disorder (FMD) in patients who initially reported one or multiple affected body sites.
  • Researchers analyzed data from the Italian Registry of Functional Motor Disorders, identifying 201 patients with one affected site and 209 with multiple sites at onset.
  • Findings indicate that FMD spread occurred in 21.4% of patients with one site affected and 13.8% with multiple sites, with psychiatric issues and non-motor symptoms linked to spread primarily in the single-site group, offering new insights into FMD's progression.
View Article and Find Full Text PDF

Background/objectives: Reports about the implementation of recommendations from acute pancreatitis guidelines are scant. This study aimed to evaluate, on a patient-data basis, the contemporary practice patterns of management of biliary acute pancreatitis and to compare these practices with the recommendations by the most updated guidelines.

Methods: All consecutive patients admitted to any of the 150 participating general surgery (GS), hepatopancreatobiliary surgery (HPB), internal medicine (IM) and gastroenterology (GA) departments with a diagnosis of biliary acute pancreatitis between 01/01/2019 and 31/12/2020 were included in the study.

View Article and Find Full Text PDF